Tanimoto Sarina's Form 4 filing
ARS Pharmaceuticals, Inc. (SPRY) · filed Nov 14, 2024
- Accession no.
- 0001415889-24-026867
- Filed
- Nov 14, 2024
- Trade date
- Nov 12, 2024
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Checked
This filing lists 4 non-derivative transactions and 0 derivative transactions. Open-market sales total $1.68M. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Tanimoto SarinaCIK 0001951291 | Officer (CHIEF MEDICAL OFFICER), 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Nov 12, 2024 | Common Stock | SSaleDisposed | −45,045 | $16.76 | −$754,954.2 | 1,301,449 | Indirect | Duplicate filing |
| Nov 12, 2024 | Common Stock | SSaleDisposed | −4,955 | $17.64 | −$87,406.2 | 1,296,494 | Indirect | Duplicate filing |
| Nov 12, 2024 | Common Stock | SSaleDisposed | −45,124 | $16.76 | −$756,278.24 | 1,253,375 | Indirect | Duplicate filing |
| Nov 12, 2024 | Common Stock | SSaleDisposed | −4,876 | $17.64 | −$86,012.64 | 1,248,499 | Indirect | Duplicate filing |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.